Medicine

Today, a brief rundown of news from PTC Therapeutics and Novartis, as well as updates from Amylyx Pharmaceuticals and Intercept Pharmaceuticals that you may have missed. Europe’s drug regulator is…

Dive Brief: Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following…

Dive Brief: An experimental antibody drug developed by Merck & Co. significantly reduced the incidence of disease due to respiratory syncytial virus infections as well as related hospitalizations in infants,…

People with advanced Parkinson’s disease have a new treatment option, as the Food and Drug Administration on Thursday approved a combination therapy from AbbVie that’s designed to provide longer-lasting movement…

Sage Therapeutics is restructuring yet again, announcing Thursday a company shakeup that will involve layoffs for about one-third of its workforce and a reprioritization of its early-stage drug pipeline. Alongside…

Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology as well as a burgeoning field of genetic medicine, RNA…

Dive Brief: The Food and Drug Administration on Tuesday approved a new device to treat non-small cell lung cancer, Novocure’s Optune Lua, which creates electric fields that its manufacturer says…

Dive Brief: Sales of Johnson & Johnson’s cancer therapy Carvykti and immune disease drug Tremfya grew strongly during the third quarter, the pharmaceutical company reported Tuesday, as new approvals helped…

Dive Brief: European life sciences venture firm Forbion on Tuesday said it has raised 2 billion euros, or more than $2.2 billion, for two of its newest investment funds. Forbion…

Danish drugmaker Lundbeck has agreed to spend $2.6 billion acquiring a young biotechnology company with an experimental brain medicine that could become a blockbuster product. The acquisition, announced Monday, has…

The Food and Drug Administration has temporarily deflected a lawsuit alleging it violated federal law by removing Eli Lilly’s obesity and diabetes drugs Zepbound and Mounjaro from an agency shortage…

An effective launch sets the stage for a new drug’s long-term success. It shapes provider and patient perceptions, drives medication starts and refills and fuels brand traction. After investing significant…

The number of medical devices with artificial intelligence technology has risen sharply in the past decade.  The Food and Drug Administration has authorized 950 AI or machine learning-enabled devices as…

Two former Pfizer executives announced late Wednesday night that they won’t support efforts by activist investor Starboard Value to shake up the giant drugmaker. “We have decided not to be…

Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody drug it’s testing against several respiratory diseases. The Waltham, Massachusetts-based…

Today, a brief rundown of news from Roche and Turnstone Biologics, as well as updates from Sanofi, Pfizer and Flagship Pioneering that you may have missed. Turnstone Biologics will lay…

For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer health business. That search may now be over. On Friday,…

Dive Brief: Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody drug it’s testing against several respiratory diseases. The Waltham, Massachusetts-based…

Dive Brief: UnitedHealth Group and CVS Health want Federal Trade Commission Chair Lina Khan and two other commissioners to recuse themselves from the agency’s lawsuit against the nation’s largest pharmacy…

Dive Brief: Eli Lilly and Insitro said they have entered into three drug development deals that offer a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs. Insitro,…

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney. The Series B funding announced Wednesday was led by…

Basecamp Research, a biotechnology startup focused on artificial intelligence, has raised $60 million in funding and signed a multi-year collaboration with the Broad Institute of MIT and Harvard. The London-based…

Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in an experimental drug from Sage Therapeutics. A mid-stage clinical trial…

Dive Brief: An experimental, muscle-preserving therapy from Scholar Rock succeeded in a Phase 3 trial in spinal muscular atrophy, positioning the biotechnology company to seek approvals in the U.S. and…

Dive Brief: GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it will make available at a not-for-profit price in low- and…

In developing drugs for rare diseases, ensuring long-term patient safety is paramount. Unlike more common conditions, rare diseases present unique challenges that make creating a comprehensive safety profile for patients both…

Dive Brief: A major California health plan has struck a novel deal with a drug manufacturer for a cheaper version of Humira, entirely cutting out pharmacy benefit managers — controversial…

Cassava Sciences has faced intense regulatory scrutiny over alleged clinical impropriety in studies of its experimental Alzheimer’s disease drug. Most recently, Cassava agreed to pay millions of dollars to resolve…

Today, a brief rundown of news from Bristol Myers Squibb and Johnson & Johnson, as well as updates from Bayer, the World Health Organization and Frazier Life Sciences that you…

Over the past decade, the medicine Enjaymo has been passed around no less than five times by developers large and small. Now it’s trading hands again, through a deal announced…

Dive Brief: Gene editing company Editas Medicines has sold off license fees and future payments it’s owed under an agreement with Vertex Pharmaceuticals to DRI Healthcare Trust for $57 million…

Dive Brief: Shortages affecting the availability of Eli Lilly’s top-selling diabetes and weight-loss drugs have now been resolved, the Food and Drug Administration said Wednesday. Lilly has assured regulators that…

The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round of talks with drugmakers begins early next year. Specifically, officials…

Dive Brief: Eli Lilly on Wednesday announced plans to spend $4.5 billion on a new facility that will use advancements in technology for research and manufacturing. Dubbed the Lilly Medicine…

Dive Brief: Gilead on Wednesday said it signed royalty-free licensing agreements with six generic drugmakers to produce and sell its HIV drug lenacapavir in countries with high incidence of the…

With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented and dissected at medical conferences throughout the year. These are…

Dive Brief: An experimental Merck & Co. drug designed to protect infants from illness caused by respiratory syncytial virus succeeded in a late-stage trial, the company said Tuesday. In a…

The U.S. government will not give Bluebird bio a green light to offer fertility support to federally insured people undergoing treatment with the biotechnology company’s gene therapy Zynteglo. In a…

Ionis Pharmaceuticals plans to push one of its rare disease drugs into late-stage testing now that a smaller trial has delivered positive results. The trial focused on Angelman syndrome, an…

Dive Brief: NGM Biopharmaceuticals, which was taken private earlier this year, has raised $122 million from venture investors to advance its recently revamped drug development plans. The Series A round,…

Dive Brief: Gilead chief medical officer Merdad Parsey will step down from his role and leave the biotechnology company early next year, Gilead said in a statement Wednesday. The planned…

Today, a brief rundown of news from Caribou Sciences and Relay Therapeutics as well as updates from Corden Pharma, Celldex Therapeutics, and Beam Therapeutics that you may have missed. Caribou…

Dive Brief: Sales of Johnson & Johnson’s depression drug Spravato accelerated in the second quarter, putting the medicine on pace to eclipse $1 billion in annual revenue this year. Globally,…

Today, a brief rundown of news from Morphic Holding as well as updates from Novartis, the Parker Institute and Agenus that you may have missed. No company other than Eli…

Cybersecurity firm CrowdStrike triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a routine software update. The firm attempted to update its Falcon…

Dive Brief: Artiva Biotherapeutics on Thursday raised $167 million in an initial public offering centered around the promise of donor-derived cell therapies for autoimmune diseases. Artiva sold 13.92 million shares at…

Boehringer Ingelheim will sell an unbranded version of its Humira biosimilar at a 92% discount to the list price of AbbVie drug for people who pay cash at pharmacies through…

Medical device companies have been steadily cutting jobs for the past 18 months, eliminating thousands of positions as firms look to lower costs, close facilities or restructure businesses. More than…

Dive Brief: A closely watched obesity pill being developed by Roche helped people in a small Phase 1 trial lose 7.3% of their body weight over four weeks when taken…

Vertex Pharmaceuticals is exploring new ways to prepare patients for intensive therapies like its sickle cell treatment Casgevy, announcing Tuesday a deal with Orum Therapeutics to develop a different kind…

Dive Brief: Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build its portfolio of heart disease drugs. Cardurion will use the…

Dive Brief: An experimental gene therapy from Lexeo Therapeutics reduced signs of heart complications in a small clinical trial of people with the rare disease Friedreich’s ataxia, the company said…

Dive Brief: An experimental cancer drug developed by Revolution Medicines shrank pancreatic tumors in about one-quarter of participants who had been followed for at least five months after treatment in…

Amylyx Pharmaceuticals achieved what all upstart drugmakers hope to accomplish. In less than 10 years, the Massachusetts-based biotechnology company identified a potential medicine, gathered enough evidence to get it approved…

The popularity of new GLP-1 drugs for weight loss is giving rise to a secondary market with large revenue potential, and companies are vying for a piece of the action.…

Dive Brief: Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. The Cambridge, Massachusetts-based company said…

The recent U.S. Supreme Court decision to overturn the Chevron doctrine could open the door to more challenges of Food and Drug Administration regulations, including the agency’s controversial rule on…

Pharmaceutical companies face a looming patent cliff over the next several years, as generic rivals could erode sales of some of the industry’s best-selling medicines. For some drugmakers, copycat competitors…

Today, a brief rundown of news from Eisai, Spark Therapeutics and Ipsen as well as updates from Element Biosciences and Novartis that you may have missed. New data from Symphony…

Dive Brief: The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending the Danish drugmaker a series of requests related to manufacturing…

With tens of billions of dollars at stake, some of the world’s largest drug companies are racing to develop pills with the same power as the weight loss shots that…

Dive Brief: The Federal Trade Commission is preparing to sue the three largest pharmacy benefit managers in the U.S. — CVS’ Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx —…

Today, a brief rundown of news from AbbVie and Skyhawk Therapeutics, as well as updates from Arcutis Biotherapeutics and Zevra Therapeutics that you may have missed. AbbVie on Wednesday named…

SciRhom, a German biotechnology startup focused on autoimmune diseases, has raised a $70 million Series A funding round that will help the company bring its first drug prospect into human…

The Federal Trade Commission on Tuesday released a long-awaited report criticizing the pharmacy benefit manager industry for manipulating the drug supply chain to profit at the expense of patients and…

Dive Brief: Biotechnology company HilleVax on Monday said it will halt development  of an experimental norovirus vaccine in infants after the shot proved ineffective in a large trial, sending shares…

Eli Lilly plans to spend $3.2 billion acquiring a Massachusetts-based biotechnology company and its experimental pill for inflammatory bowel disease. Announced Monday, the all-cash deal has Lilly buying all the…

Dive Brief: Two years after canceling an initial public offering, Artiva Biotherapeutics has filed a new proposal centered around plans to develop a donor-derived cell therapy for autoimmune disease. The…

Dive Brief: UniQure will sell a gene therapy production plant in Lexington, Massachusetts, to contract manufacturer Genezen in a deal designed to reduce the biotechnology company’s operating expenses. Genezen will…

Dive Brief: Cartesian Therapeutics on Tuesday said an experimental cell therapy it's developing succeeded in a mid-stage clinical trial of people with the rare autoimmune condition myasthenia gravis, but shares…

Two of last year’s largest biotechnology company acquisitions centered on a new type of treatment for schizophrenia. By the end of September, the first of those therapies could win Food…

Today, a brief rundown of news from Beacon Therapeutics and Regeneron Pharmaceuticals, as well as updates from Vertex Pharmaceuticals, Johnson & Johnson and Codexis that you may have missed. Gene…

Dive Brief: CureVac, a specialist in messenger RNA-based therapies, disclosed Wednesday plans to lay off 30% of its workforce as part of a “significant strategic restructuring” that will direct the…

The Food and Drug Administration on Tuesday approved a new Alzheimer’s disease drug from Eli Lilly, several weeks after a panel of independent experts unanimously recommended its clearance. The drug,…

The U.S. government has awarded $176 million to vaccine maker Moderna for development of an mRNA-based influenza shot. The funding was awarded through the Biomedical Advanced Research and Development Authority,…

Dive Brief: Eli Lilly is expanding further into radiopharmaceuticals, inking a deal with Radionetics Oncology that gives it an option to later acquire the San Diego biotechnology company for $1…

Dive Brief: Eisai and Bristol Myers Squibb will cancel a collaboration on a dual-acting drug being developed to treat lung and ovarian cancer, Eisai said Monday. The termination is the…

After months of searching, the drug hunters had tracked down the prized game they believed could help launch the next chapter of their company. The team from Biohaven Pharmaceutical moved…

Immune drug developer Alumis has raised $210 million in one of the biotechnology sector’s largest initial public offerings this year. Still, the IPO announced Thursday comes in below projections Alumis…

Dive Brief: The U.S. Supreme Court overturned the Chevron doctrine on Friday in a decision that could dramatically limit federal agencies’ regulatory power.  In a 6-3 vote, the high court…

Today, a brief rundown of news from PTC Therapeutics, Esperion Therapeutics and Coherus Biosciences, as well as updates from Sanofi, Lantheus Holdings and Forbion that you may have missed. Drug…

Dive Brief: The Food and Drug Administration has rejected a gene therapy developed by Rocket Pharmaceuticals for a rare type of inherited immunodeficiency, the biotechnology company disclosed Friday. According to…

Dive Brief: Advisers to the Centers for Disease Control and Prevention on Thursday unanimously recommended Merck & Co.’s recently approved pneumococcal vaccine for use in adults aged 65 years and…

Dive Brief: 2seventy Bio is shrinking further, announcing Thursday the sale of a hemophilia A research program, along with associated technology rights, to partner Novo Nordisk. 2seventy and Novo first…

Dive Brief: Shares of Moderna, Pfizer and GSK fell as advisers to the Centers for Disease Control and Prevention discussed updated guidelines for RSV vaccination at a Wednesday meeting. The…

Dive Brief: Novo Nordisk will end a Phase 3 clinical trial of a hypertension drug it bought for up to $1.3 billion last year because treatment didn’t appear to be…

Ozempic and GLP-1 drugs like it became household names due to their potent weight loss benefits, and are now proving useful in a slew of other chronic conditions. Women are…

Dive Brief: Wave Life Sciences on Tuesday said it will meet with regulators to discuss what kind of evidence would be needed to support an accelerated approval application for an…

Dive Brief: Novo Nordisk will spend $4.1 billion to build a new U.S. factory in North Carolina, the latest multibillion-dollar investment by the Danish drugmaker to expand production of its…

Dive Brief: Novo Nordisk on Sunday disclosed detailed clinical trial results for an experimental hemophilia treatment dubbed Mim8, showing once-weekly and once-monthly doses of the antibody drug controlled bleeding in…

Today, a brief rundown of news from Altimmune, Jiangsu Hengrui, Eli Lilly and others that you might have missed from over the weekend, when the American Diabetes Association held its annual…

Dive Brief: Amazon has expanded its generic drug savings program to Prime members on Medicare, throwing open the program’s doors to a major population of medication users — if Amazon…

Dive Brief: Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage clinical trial that study monitors recommend the company stop testing…

An experimental weight loss shot developed by Denmark-based Zealand Pharma helped people with obesity lose as much as 9% of their body weight over four months, results the company said…

Today, a brief rundown of news from Jazz Pharma, Vanda Pharmaceuticals, ITM, Ashibio and Novartis that you might have missed from earlier in the week. An experimental medicine that Jazz…

Peter Marks is again at the center of a controversial Food and Drug Administration decision on a gene therapy for Duchenne muscular dystrophy. Twice now, the high-ranking FDA leader has…

The Food and Drug Administration has substantially loosened limits on the first gene therapy for Duchenne muscular dystrophy in a decision that could greatly expand its use even as questions…

Dive Brief: PTC Therapeutics said Thursday it can resume a Phase 2 trial of its Huntington’s disease drug in the U.S., following the Food and Drug Administration’s review of data…

Today, a brief rundown of news from Belharra Therapeutics, AstraZeneca, Regenxbio and Tasyha Gene Therapies. Sanofi will work with biotechnology startup Belharra Therapeutics to develop small molecule drugs for inflammatory…

Dive Brief: Intra-Cellular Therapies plans to seek clearance to sell its medicine Caplyta for patients with depression after a second-late stage study of the drug succeeded.  Caplyta, also known as…

Dive Brief: The Food and Drug Administration on Monday approved a new vaccine from Merck & Co. that protects against 21 types of the bacteria that causes pneumococcal disease. The…

The failure of a Pfizer medicine for Duchenne muscular dystrophy adds new uncertainty around the effectiveness of gene therapy for the muscle-wasting condition, days before the Food and Drug Administration…

Today, a brief rundown of news from Takeda and the Food and Drug Administration, as well as updates from Insmed, J.P. Morgan and Bristol Myers Squibb that you may have…

Dive Brief: Telix, an Australia-based developer of radiopharmaceutical drugs for cancer, has canceled plans to raise roughly $200 million via an initial public offering on the Nasdaq stock exchange.  The…

AbbVie is securing its place in an emerging gastrointestinal disease drug field, paying China-based FutureGen Biopharmaceutical $150 million in immediate and near-term fees for rights to an antibody drug targeting…

Dive Brief: Moderna said its next-generation COVID-19 vaccine succeeded in a Phase 3 study, offering increased effectiveness for adults. The vaccine, known as mRNA-1283, is designed to fight newer strains…

The Supreme Court on Thursday unanimously ruled an anti-abortion group contesting the Food and Drug Administration’s approval of the abortion pill mifepristone does not have a legal basis to sue,…

Dive Brief: Flagship Pioneering will partner with biotechnology startup ProFound Therapeutics to search for promising drug candidates for obesity that Pfizer, under a deal struck with Flagship last year, may…

Pfizer’s experimental gene therapy for Duchenne muscular dystrophy didn’t improve the motor function of young boys enrolled in a late-stage trial meant to provide a decisive verdict on the treatment’s…

Dive Brief: The Food and Drug Administration on Monday cleared a new treatment option for the rare liver disease primary biliary cholangitis, granting an accelerated approval to Ipsen’s drug Iqirvo.…

Approval of Eli Lilly’s experimental Alzheimer’s disease drug donanemab would help drive sales of Eisai and Biogen’s rival medicine Leqembi, analysts wrote after a Food and Drug Administration panel on…

Dive Brief: Moderna on Monday said a combination flu and COVID-19 shot it’s developing met the goal of a late-stage study, eliciting higher immune responses to the two viruses than…

An experimental and closely watched medicine for Alzheimer’s disease is one step closer to approval, after receiving support from a panel of experts who advise the Food and Drug Administration.…

As healthcare moves toward the shared goal of improving patient care more economically, stakeholders across the healthcare ecosystem are increasingly aligned with the principles of value-based care. Value-based care is…

Dive Brief: Seres Therapeutics plans to sell all the rights to its microbiome pill to Nestlé Health Science as it struggles to fund operations. Under a nonbinding memorandum of understanding…

A group of advisers to the Food and Drug Administration on Wednesday unanimously recommended that COVID-19 vaccines be updated to cover coronavirus strains with a family known as JN.1 ahead…

After a turbulent few years, 2024 has given the biotechnology industry some signs of a return to normalcy. For one, venture investment appears to have stabilized at levels seen prior…

Today, several brief updates from BioPharma Dive Reporter Gwendolyn Wu, who spent this week attending BIO’s annual meeting in San Diego, as well as notes on Geron, AbbVie and Deerfield…

Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained momentum over the last several years. But some proponents believe…

Dive Brief: Expert advisers to the Food and Drug Administration will need to weigh whether Eli Lilly’s experimental Alzheimer’s disease drug donanemab is widely effective or should be restricted only…

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. British drugmaker GSK is investing further in nucleic acid drug development, reaching…

Dive Brief: Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet, the companies said Wednesday.…

Today, a brief rundown of news from Eli Lilly, Cytokinetics and AbbVie, as well as updates from Gilead and the National Institutes of Health that you may have missed from…

Dive Brief: Illumina’s board of directors has approved a spinoff of Grail, targeting June 24 as the date the cancer blood test maker will regain its independence. Illumina agreed to…

Medical experts who advise the Food and Drug Administration are not convinced MDMA is ready for general use to help treat post-traumatic stress disorder, recommending at a meeting Tuesday the…

Dive Brief: An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday.…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Liquid biopsy has emerged as a revolutionary tool for clinical trials, offering cellular and cell-free methods that provide valuable insights into disease progression and treatment response. Circulating tumor cells (CTCs)…

Two years ago, a drug called Enhertu changed the way doctors thought about treating an aggressive form of breast cancer, making it important to know not only whether their patients’…

An accelerated approval for Gilead Sciences’ cancer drug Trodelvy could be in question after the company disclosed Thursday afternoon that a confirmatory trial failed to meet its main objective. In the…

The Food and Drug Administration on Friday approved a third vaccine for respiratory syncytial virus, clearing a shot from biotechnology company Moderna one year after granting a green light to…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Food and Drug Administration scientists have reservations about a potential new treatment for post-traumatic stress disorder that’s currently up for approval. Developed by an unusual company called Lykos Therapeutics, the…

Otsuka America, a subsidiary of the Japanese drug and device maker, this month launched a new company focused on digital health. The firm, called Otsuka Precision Health, will roll out…

Dive Brief: Immunovant told investors Wednesday that it’s shifting resources to focus on a less advanced experimental autoimmune disease treatment that appears more promising for future development. The company now…

Dive Brief: Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for $1.3 billion in cash upfront and as much as $1.7…

Dive Brief: Gameto, a biotechnology company developing new treatments for fertility, has raised $33 million in venture capital funding to advance technology it says could shorten in vitro fertilization cycles,…

Dive Brief: Agios Pharmaceuticals has agreed to sell to Royalty Pharma rights to royalties on a brain cancer drug it invented and sold to Servier. Per deal terms announced Tuesday,…

New Jersey-based drugmaker Insmed gained more than $3 billion in market value Tuesday after reporting clinical trial results for an experimental lung disease drug that impressed analysts. Data from the…

Artificial intelligence (AI) has sparked a revolution in the pharmaceutical industry, reshaping the way we approach complex biological challenges. “From personalized medicine to unraveling the mysteries of our DNA, we’re…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Dive Brief: Shares in Cytokinetics sank by about one-fifth Thursday on news of a funding deal the biotechnology company struck with Royalty Pharma, in which it traded away a stake…

Dive Brief: German drugmaker Merck KGaA agreed to buy Mirus Bio for $600 million to build expertise in a critical part of viral vector-based gene therapy production. Merck KGaA is…

Orna Therapeutics, a young biotechnology company focused on a flashy area of genetic research, is expanding through the acquisition of another well-funded startup. As its name suggests, the startup, ReNAgade…

Eli Lilly plans to spend another $5.3 billion building production capacity for its popular obesity and diabetes drugs, responding to immense demand for the medicines with what it claims is…

A top Food and Drug Administration official on Friday again advocated for the speedy approval of gene therapies for rare diseases. But he didn’t drop any clues on where the…

An older form of hormone therapy taken to ease the symptoms of menopause could increase the risk of ovarian cancer, according to results released Thursday from two studies involving tens…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Dive Brief: Biogen is scooping up a closely held immunology startup to bring more diversity to a pipeline best known for neurology products. Per deal terms, Biogen will pay $1.15…

Pfizer, already in the midst of an aggressive effort to trim spending, on Wednesday disclosed new plans to cut at least $1.5 billion in additional costs over the next several…

Eli Lilly is partnering with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer, agreeing to a deal that will pay the startup $60 million upfront. Per terms announced Tuesday,…

Dive Brief: AstraZeneca’s plan to reach $80 billion in sales by 2030 relies heavily on a slate of roughly one dozen cancer drugs it expects will become blockbuster sellers at…

British biotechnology startup Pheon Therapeutics has raised another $120 million in venture funding, riding a wave of investor interest in the type of cancer medicines, known as antibody-drug conjugates, it…

Forbion, a well-known backer of life sciences startups, is leading an investment round for a newly launched biotechnology company focused on diseases that affect nerve cells. The company, Progentos Therapeutics,…

Dr. Zocca brings more than 20 years of experience in the biotechnology field and has founded and co-founded several biotech spinouts. Her focus on translational and clinical immune oncology has…

Biogen and Ionis Pharmaceuticals are stopping development of an experimental drug for ALS following new clinical trial results that didn’t meet the companies’ expectations. The trial, which enrolled almost 100…

Dive Brief: An experimental Roche drug helped people with obesity lose an average of nearly 19% of their body weight over six months, after adjusting for placebo, in an early-stage…

A once-weekly form of insulin being developed by Eli Lilly proved just as effective at controlling blood sugar in adults with diabetes as commonly used daily injections, according to results…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Dive Brief: The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has…

New data from two late-stage studies of an experimental Bayer drug show it reduced the frequency and severity of common symptoms of menopause, supporting the company’s case for seeking regulatory…

Four life science investors are pouring $400 million into a new biotechnology startup that’s licensed a portfolio of weight loss medicines from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals, according to a…

San Francisco-based Bolt Biotherapeutics on Tuesday said it is ending development of its lead cancer drug, laying off half its staff and changing up its leadership. Alongside announcing first quarter…

One of the developers behind the Alzheimer’s disease drug Leqembi has set new revenue expectations that some analysts see as more practical than previous guidance. On Wednesday, Japan-based Eisai predicted…

FogPharma and Artbio, two buzzy biotechnology companies, are betting they can combine their respective technologies to design a new type of radiopharmaceutical drug for cancer. The companies didn’t disclose financial…

German pharmaceutical company Bayer eliminated 1,500 roles during the first three months of the year as part of a company makeover CEO Bill Anderson promised last year. Speaking on a…

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Sanofi is adding to its portfolio of rare disease therapies,…

Takeda Pharmaceutical is betting potentially billions of dollars on drugs designed to slow Alzheimer’s disease by harnessing the immune system. Through a deal announced Monday, Takeda has secured an exclusive…

Comorbidities are associated with a lack of representation in randomized controlled trials. As a result, it’s often unclear whether trial findings and subsequent treatment recommendations apply to those with comorbidities. …

Novo Nordisk is again turning to a Flagship Pioneering startup to find new weight loss drugs, announcing on Thursday a deal with Metaphore Biotechnologies to develop up to two medicines…

Dive Brief: Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced…

Dive Brief: Biotechnology startup Maze Therapeutics has licensed a Pompe disease drug to Shionogi, five months after a challenge from the Federal Trade Commission caused Sanofi to back out of…

Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for respiratory syncytial virus due to “administrative constraints,” extending a review the…

BioPharma Dive is testing out a new format rounding up smaller updates from around the industry. Have thoughts on what could make this type of story better? Drop us a…

Dive Brief: Royalty Pharma will pay biotechnology startup ImmuNext $525 million for the right to earn royalties and milestone payments from an autoimmune disease drug the privately held company licensed…

Dive Brief: Takeda plans to simplify how its workforce is organized, cut spending and slim down its drug pipeline in a restructuring aimed at improving its profit margin over the…

Dive Brief: AstraZeneca will no longer manufacture or supply its COVID-19 vaccine Vaxzevria, announcing Tuesday it is voluntarily withdrawing the shot due to a “decline in demand,” a spokesperson wrote in…

Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay…

Dive Brief: Verve Therapeutics has treated the first participant in a recently begun clinical trial of the company’s backup gene editing therapy for heart disease, about one month after a…

A young boy enrolled in a clinical trial testing an experimental Pfizer gene therapy for Duchenne muscular dystrophy has died, the company revealed Tuesday in a letter posted online by…

Physicians at Children’s National Hospital in Washington, D.C., last week collected the stem cells of a young boy with sickle cell disease in preparation for what will be the first…

Gossamer Bio has sold rights to an experimental drug that could rival a new medicine from Merck & Co., in a deal at least one analyst believes “bodes well” for…

When it comes to data-driven science, your results are only as good as your data and your software. Whether free or premium, your choice of software will greatly impact your…

Cancer research is always evolving, as scientists search for ways to combat the tricks tumors use to evade drug therapies. In the last decade alone, immunotherapies, targeted therapies, antibody-drug conjugates…

Dive Brief: The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna in 2021 has ended after the two companies “mutually agreed”…

Dive Brief: An experimental drug from CG Oncology has driven bladder cancers into remission in about three-quarters of people who received it in a Phase 3 trial, matching results the…

Mariana Oncology arrived at the J.P. Morgan Healthcare Conference this past January with momentum. The radiopharmaceutical drug developer had secured $175 million in fresh funding four months prior and, in…

Dive Brief: Amgen shares soared by double digits Friday following its announcement an obesity drug it’s developing has shown enough promise to warrant advancing into late-stage testing. On an earnings…

Dive Brief: Novartis is expanding its pipeline of radiopharmaceutical drugs, announcing Thursday it has agreed to pay $1 billion to acquire biotechnology company Mariana Oncology. Mariana, which specializes in the…

Dive Brief: Sales of Novo Nordisk’s obesity drug Wegovy slowed over the first three months of 2024, compared to the fourth quarter last year, as lower realized prices and continued…

Pfizer’s rare disease drug Vyndaqel may be its least well known blockbuster medicine. The pharmaceutical company’s COVID-19 vaccine became a household name during the pandemic, while its other top-sellers for…

Dive Brief: GSK on Wednesday raised its financial forecasts for the year following strong quarterly sales of its vaccines and HIV medicines.  GSK said vaccine sales surged 16% compared to the…

Federal officials said a new rule expanding regulatory oversight of laboratory-developed tests will protect patients from inaccurate results while maintaining access to important diagnostics. But some industry experts disagree, arguing…

Eli Lilly expects that, by the second half of this year, it will be able to manufacture at least 50% more sellable doses of the main ingredient in its GLP-1…

Dive Brief: Prime Medicine will soon begin the first clinical trial of a new drugmaking technique known as prime editing, following the Food and Drug Administration’s clearance of its application…

Dive Brief: The Food and Drug Administration on Monday released a final rule strengthening its authority over laboratory developed tests, or LDTs, advancing a policy that has drawn fierce opposition…

Biogen plans to increase the number of salespeople selling the company’s prized drug for Alzheimer’s disease, now that some of the initial challenges launching it have been worked through. The…

Dive Brief: Biogen has seen “encouraging early trends” in the launch of its postpartum depression pill Zurzuvae, revealing in first quarter earnings drug sales that surpassed the estimates of Wall…

Dive Brief: Regeneron Pharmaceuticals is upping its investment in genetic medicine, announcing Thursday a $100 million deal with CRISPR drug developer Mammoth Biosciences. Through their collaboration, the companies plan to…